

Title (en)  
FORMULATIONS FOR PARENTERAL USE OF ESTRAMUSTINE PHOSPHATE WITH IMPROVED PHARMACOLOGICAL PROPERTIES

Title (de)  
PARENTERAL ANZUWENDENDE ESTRAMUSTINPHOSPHATHALTIGE ARZNEIZUSAMMENSETZUNGEN MIT VERBESSERTEN PHARMAKOLOGISCHEN EIGENSCHAFTEN

Title (fr)  
FORMULATIONS POUR USAGE PARENTERAL D'ESTRAMUSTINE PHOSPHATE A PROPRIETES PHARMACOLOGIQUES AMELIOREES

Publication  
**EP 1212040 A1 20020612 (EN)**

Application  
**EP 00956409 A 20000803**

Priority  
• EP 0007679 W 20000803  
• GB 9921954 A 19990916

Abstract (en)  
[origin: WO0119338A1] A pharmaceutical formulation which comprises a parenterally acceptable carrier or diluent, estramustine phosphate, a sulfoalkyl ether cyclodextrin and human albumin. The formulation can be administered according to a combined chemotherapy regimen in association with one or more chemotherapeutic agents. The formulation also enables the estramustine phosphate to be administered with no side effects at the site of injection.

IPC 1-7  
**A61K 9/08**; **A61K 47/40**; **A61K 31/565**; **A61P 35/00**; **A61K 31/66**; **A61K 47/42**

IPC 8 full level  
**A61K 31/662** (2006.01); **A61K 38/38** (2006.01); **A61K 47/40** (2006.01); **A61K 47/42** (2006.01); **A61P 1/00** (2006.01); **A61P 1/18** (2006.01); **A61P 11/00** (2006.01); **A61P 15/00** (2006.01); **A61P 35/00** (2006.01)

CPC (source: EP KR)  
**A61K 9/0019** (2013.01 - EP); **A61K 31/661** (2013.01 - EP); **A61K 38/38** (2013.01 - EP); **A61K 47/40** (2013.01 - EP); **A61K 47/42** (2013.01 - EP KR); **A61P 1/00** (2017.12 - EP); **A61P 1/18** (2017.12 - EP); **A61P 11/00** (2017.12 - EP); **A61P 15/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP)

C-Set (source: EP)  
1. **A61K 38/38** + **A61K 31/715** + **A61K 31/66**  
2. **A61K 38/38** + **A61K 31/715** + **A61K 31/565**  
3. **A61K 38/38** + **A61K 2300/00**

Citation (search report)  
See references of WO 0119338A1

Designated contracting state (EPC)  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)  
**WO 0119338 A1 20010322**; AU 6836300 A 20010417; AU 777763 B2 20041028; BR 0014063 A 20040629; CA 2385063 A1 20010322; CN 1177583 C 20041201; CN 1374858 A 20021016; CZ 2002943 A3 20020814; EA 005308 B1 20041230; EA 200200369 A1 20020829; EP 1212040 A1 20020612; GB 9921954 D0 19991117; HK 1047227 A1 20030214; HU P0202621 A2 20021228; IL 148409 A0 20020912; JP 2003509355 A 20030311; KR 20020059405 A 20020712; MX PA02002859 A 20030721; NO 20021306 D0 20020315; NO 20021306 L 20020424; NZ 517631 A 20040130; PL 353954 A1 20031215; SK 3452002 A3 20020806; ZA 200201743 B 20030528

DOCDB simple family (application)  
**EP 0007679 W 20000803**; AU 6836300 A 20000803; BR 0014063 A 20000803; CA 2385063 A 20000803; CN 00812952 A 20000803; CZ 2002943 A 20000803; EA 200200369 A 20000803; EP 00956409 A 20000803; GB 9921954 A 19990916; HK 02108529 A 20021126; HU P0202621 A 20000803; IL 14840900 A 20000803; JP 2001522973 A 20000803; KR 20027003498 A 20020315; MX PA02002859 A 20000803; NO 20021306 A 20020315; NZ 51763100 A 20000803; PL 35395400 A 20000803; SK 3452002 A 20000803; ZA 200201743 A 20020301